The Second Multicenter Hemophilia Cohort Study

Key facts

Sponsor

National Cancer Institute (NCI)

Principal Investigator

James J Goedert, M.D., M.D

National Cancer Institute (NCI)

Enrollment

2565 enrolled

Eligibility

13 years · All sexes

Timeline

2001 – 2013

Study locations (30)

• University of Arizona, Tucson, Arizona, United States
• University of California, Davis, Davis, California, United States
• Children's Hospital of Orange County, Orange, California, United States
• University of California, San Francisco, San Francisco, California, United States
• University of Colorado, Denver, Colorado, United States
• Christiana Hospital, Wilmington, Delaware, United States
• Georgetown University, Washington D.C., District of Columbia, United States
• Childrens National Medical Center, Washington D.C., District of Columbia, United States
• Emory University, Atlanta, Georgia, United States
• University of Illinois, Chicago, Illinois, United States
• Childrens Memorial Hospital, Chicago, Chicago, Illinois, United States
• St. Vincent's Hospital, Indianapolis, Indiana, United States
• Tulane University, New Orleans, Louisiana, United States
• Wayne State University Hutzel Hospital, Detroit, Michigan, United States
• University of Minnesota, Minneapolis, Minnesota, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

Multicenter Hemophilia Cohort Study

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Combined hepatocellular carcinoma and cholangiocarcinoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT06902246
  Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
  University of Miami
• RECRUITINGPHASE1NCT07419841
  A Phase 1 Study of the Safety and Tolerability of CTX-10726
  Compass Therapeutics
• RECRUITINGPHASE1NCT07493044
  An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma
  Guangzhou FineImmune Biotechnology Co., LTD.
• RECRUITINGPHASE2NCT07122089
  Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis
  Center Eugene Marquis
• RECRUITINGPHASE1, PHASE2NCT07482059
  A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma
  West China Hospital
• RECRUITINGPHASE2NCT06254248
  Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma
  Assistance Publique - Hôpitaux de Paris
• RECRUITINGNANCT07469319
  Biannual Screening for HCC Offered to Patients With Cirrhosis. Introducing Surveillance for Hepatocellular Carcinoma (HCC) in the Central Denmark Region Using Ultrasound and Alpha-Fetoprotein to Reduce HCC-Related Mortality in Patients With Compensated Non-Viral Cirrhosis
  University of Aarhus
• RECRUITINGEARLY PHASE1NCT07242417
  TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors
  Beijing GoBroad Hospital

See all trials for Combined hepatocellular carcinoma and cholangiocarcinoma →